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Abstract
Obesity is a prevalent condition with several associated co-morbidities including 
the development of metabolic diseases. In obesity there is immune cell infiltration 
into the white adipose tissue and this is associated with the generation of inflam-
mation and insulin resistance (IR). A large majority of the infiltrating leukocytes 
in obese adipose tissue are pro-inflammatory macrophages, which upon activation 
induce a switch in metabolism from oxidative phosphorylation, as is utilised by 
macrophages in lean adipose tissue, towards aerobic glycolysis. The signalling path-
ways evoked in the recruited macrophages induce the release of pro-inflammatory 
cytokines, in signalling pathways which directly interfere with insulin signalling 
and thus induce a state of IR. As macrophages appear to play such a pivotal role in 
the generation of IR and are the largest leukocyte population in the adipose tissue, 
they provide a promising therapeutic target. Indeed, there are several strategies 
currently being studied to induce a ‘switch’ in macrophages associated with obese 
adipose tissue, towards the phenotype of those associated with lean adipose tissue, 
with arguably the most promising being those strategies designed to target the 
metabolic pathways within the macrophages. This chapter will discuss the polarisa-
tion and activation of macrophages within lean and obese adipose tissue and how 
these cells can be targeted therapeutically.
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1. Introduction
Obesity is defined as abnormal or excessive fat accumulation and is linked with 
increased risk of development of multiple co-morbidities, including cardiovascular 
disease, type 2 diabetes, musculoskeletal disorders and certain cancers. Obesity and 
its associated co-morbidities are a significant health concern facing the global popu-
lation. Worldwide obesity has tripled since 1975, with 39% of adults considered 
overweight and 13% considered obese [1]. This situation is prominent in childhood, 
with 41 million of the global under five population overweight or obese [1].
Obesity induces a state of low-grade systemic inflammation, characterized by 
increased serum levels of pro-inflammatory mediators, including C Reactive Protein 
(CRP), Tumour Necrosis Factor (TNF)-α, Interleukin (IL)-1β and IL-6, which 
contributes to metabolic dysfunction and insulin resistance (IR) [2]. Although the 
mechanisms underlying this inflammatory response are not fully understood, activa-
tion of adipose tissue macrophages (ATM) contributes to this inflammatory state, 
and therefore to the development of insulin resistance (IR) [3, 4]. Conversely, in lean 
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individuals the immune repertoire constitutes a more anti-inflammatory phenotype, 
with ATM alongside regulatory T cells (Tregs) releasing cytokines such as IL-10 
and transforming growth factor (TGF)-β, which increase insulin sensitivity [5]. 
Therefore, the role of ATM in metabolic function is clearly an area of interest, indeed 
transcriptional profiling has identified how quickly macrophages can respond and 
adapt to alterations in their microenvironment [6]. This chapter will focus on the 
role macrophages play in the pathogenesis of metabolic disorders and explore if re-
education of these cells provides a target for therapeutic intervention in obesity and 
its related co-morbidities.
2.  The microenvironment of the adipose tissue in lean  
and obese individuals
Obesity historically was believed to be due to a combination of genetic predis-
position and environmental factors, however, more recently it has been recognised 
that immunological factors can also contribute to the pathogenesis of obesity. 
Indeed, while over 30 gene loci combinations have been associated with the devel-
opment of obesity and metabolic disease, these loci are only associated with 2–3% 
of the incidence of these conditions [7]. Further the energy-dense modern Western 
diet combined with a sedentary lifestyle undoubtedly adds to the obesity epidemic. 
Recent work has identified the links between dysbiosis in the intestinal microbiome 
and immune cell activation, linked to the ingestion of high-fat, low-fibre diets, and 
the development of obesity [8].
2.1 The role of the microbiome
The intestinal microbiome is essential for processing dietary polysaccharides 
and has been identified as a key regulator of systemic inflammation in obesity 
[9]. Mouse studies are routinely used to study the mechanisms underlying obesity 
and metabolic disease. Due to the nature of obesity being largely related to diet, 
diet-induced models are often favoured over genetic models (for example, leptin 
deficient ob/ob mice). Indeed, studies using a high-fat diet (HFD; equivalent to 
60% animal-derived fats in the diet) have been used to study the potential implica-
tions of alteration in the microbiome related to diet as well as other obesity-related 
pathogenesis. It has been shown that the microbiome in obese mice has an increased 
capacity to harvest energy from the diet compared to the microbiome from lean 
mice [10]. Microbiome transfer studies, in which intestinal microbiota from mice 
raised in conventional housing was transferred into germ-free mice, induced a 60% 
increase in body fat and IR within 14 days, despite a reduction in food consumption 
[11]. The transfer of microbiota-derived products such as lipopolysaccharides and 
peptidoglycans, have shown to promote metabolic endotoxemia, which induces pro-
inflammation in adipose tissue [12]. In contrast, the microbiota of the gut bacterial 
fermentation of dietary fibre was shown to have anti-inflammatory effects [12]. 
Indeed, it was shown that the transfer of intestinal microbiota from lean donors 
increased the insulin sensitivity in individuals with metabolic syndrome [13].
2.2 Adipose tissue
Adipose tissue (AT) is an important metabolic organ, which helps orchestrates 
metabolic and endocrine functions as well as immune responses [12]. AT functions 
to store excess nutrients as triacylglycerides and releases fatty acids in the fasted 
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state, provide cold insulation and protection of vital organs. In the AT of obese 
individuals, there is significant adipocyte hyperplasia and adipose tissue hypertro-
phy [14]. AT consists of mature adipocytes, pre-adipocytes, fibroblasts, endothelial 
cells, histocytes and populations of immune cells including monocytes, macro-
phages, natural killer (NK) cells, innate lymphoid cells (ILCs) and lymphocytes. AT 
is classified into three categories, namely white (WAT), beige or ‘brite’ (beige/brite) 
and brown (BAT). WAT accounts for approximately 50% of body mass and can 
release free fatty acids (FFA) into circulation when glucose levels are low. Whilst 
BAT plays an important role in thermogenesis and the production of heat [15].
The AT of obese individuals is in a state of chronic low-grade inflammation 
with marked infiltration various pro-inflammatory immune cells such as CD8 
cells, NK cells, ILC1, Th1 cells, neutrophils and pro-inflammatory macrophages 
[16]. Conversely, the immune repertoire of AT from lean individuals comprises 
anti-inflammatory cell populations, including eosinophils, ILC2, Tregs, Th2 cells 
and anti-inflammatory macrophages [16] (Figure 1). In lean mice, ATM consti-
tutes approximately 5% of cells, conversely in obese mice ATM can account for 
up to 50% of the cells [3]. Whilst in lean human AT, ATM comprises 4% of cells 
compared to 12% in excess adiposity [17]. In addition to macrophages, lymphocytes 
and ILCs also play roles in the regulation of AT inflammation, the roles of which 
seem to largely involve supporting the polarisation state of the ATM populations. 
For example, eosinophils provide a source of IL-4 promoting an M2 phenotype. 
In obese mice adipose eosinophils are decreased, whilst depletion of eosinophils 
results in increased M1 ATM, weight gain and systemic IR [18]. Furthermore, ILC2 
Figure 1. 
Immune cell composition of adipose tissue in a lean and obese state. In the lean state, eosinophils and type 
2 innate lymphoid cells (ILC2s) produce Th2 cytokines (IL-4, IL-5 and IL-13), which promotes eosinophil 
recruitment and anti-inflammatory polarisation of macrophages towards an M2 phenotype, which is 
supported in the normoxic state of lean adipose tissue. In turn, M2 macrophages secrete anti-inflammatory 
cytokines such as IL-10. In the obese state, adipocyte hypertrophy, hyperplasia and hypoxia cause necrotic 
adipocytes, resulting in pro-inflammatory state and macrophage recruitment, forming crown like structures 
(CLS) surrounding the adipocytes. These macrophages are polarised towards an M1 phenotype and secrete the 
pro-inflammatory cytokines IL-6, IL-1β and TNF-α.
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have been identified as a source of IL-5, a key cytokine in eosinophil recruitment. 
Thus, accumulation of eosinophils and maintenance of M2 ATM relies on ILC2 [19].
2.3 The role of the adaptive immune system in obesity
The adaptive immune system also plays an important role in obesity and meta-
bolic disease. B cells have been shown to be involved in obesity induced inflam-
mation and IR [20]. In obese mice, there was an identified increased in IgG+B cells 
and IgG production, associated with activation of M1 ATM, increased Th1 cells 
and conversely, attrition of Treg cells [21]. In addition, transferring B cells into B 
cell deficient mice induced IR [20]. Furthermore, in obese mice, there is increased 
CD8+ effector T cell recruitment in epididymal AT. Interestingly, it is reported that 
CD8+ T cells precede macrophage infiltration and deletion of CD8+ T cells resulted 
in reduced macrophage infiltration and AT inflammation whilst improving IR [22]. 
Conversely, both Treg cells and iNKT cells are negatively associated with obesity-
induced inflammation and are enriched in lean AT. Indeed, both these immune cells 
are known to secrete IL-10 which promotes M2 macrophage polarisation [23, 24].
2.4 Adipose tissue macrophages
ATMs appear to play a major role in the regulation of obesity-related inflamma-
tion, with different macrophage phenotypes associated with divergent roles in the 
AT. In lean animals, ATM function to maintain the homeostatic micro-environment 
in AT by taking up excess lipids and phagocytosing dead adipocytes. Broadly 
speaking macrophages present in lean AT are of an M2 phenotype, which have 
been shown to suppress inflammation in AT [25]. Furthermore, M2 macrophages 
in lean AT have been associated with brown fat activation and ‘beiging’ of WAT in 
mouse models of obesity, via expression of tyrosine hydroxylase, which induces 
thermogenesis [26, 27]. However, this process has recently been queried, with 
IL-4-stimulated macrophages failing to generate sufficient levels of catecholamines 
to contribute to adipose tissue adaptive thermogenesis [28]. Conversely, excess lipid 
uptake in obese AT, induces M1 polarisation and along with excess lipid droplets, 
immune cells and necrotic adipocytes this forms a component called ‘crown-like’ 
structures (CLS) [29, 30]. Indeed, it has been shown that more than 90% of all 
macrophages in WAT of obese mice and humans are localized to dead adipocytes 
[31]. This metabolic activation of M1 macrophages in obese AT is associated with 
increased pro-inflammatory cytokines in the AT and recruitment and activation of 
M1 macrophages in the AT [32].
ATM in lean AT is considered a resident macrophage population, which origi-
nates from yolk-sac progenitors and self-renews via proliferation under homeostatic 
conditions. Over time into adulthood resident ATMs are replaced with circulating 
monocytes derived from bone marrow [33]. Using mouse bone marrow chimera 
experiments, following transplanting donor CD45.1+ bone marrow into recipient 
CD45.2+ mice, and maintenance on obesity-inducing HFD, 85% of the ATM were 
donor-derived compared to 15% that were recipient-derived [3]. Interestingly, the 
polarization of macrophages in obesity from an M2 to an M1 phenotype has been 
mainly attributed to the recruitment of monocytes to AT, rather than the conver-
sion of tissue resident M2 macrophages [34]. Murine monocytes can be classified 
through the expression of Ly6C, with Ly6Chi monocytes considered inflammatory. 
In the steady state Ly6Chi monocytes differentiate into Ly6Clo monocytes in the 
circulation, which are believed to differentiate into M2 macrophages in the tissue. 
However, in obese AT in response to inflammatory stimuli such as the monocyte 
chemoattractant CCL2, Ly6Chi macrophages are recruited to the AT where they 
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differentiate to M1-like ATM [25]. Indeed, in absence of Ccl2 expression macro-
phages expressed an M2 gene profile [35].
ATM represents the largest population of leukocytes within the AT and plays 
many vital homeostatic roles including tissue remodelling and insulin sensitivity. 
However, with progressive obesity ATM are the key mediators of inflammation, IR 
and the impairment of adipocyte function.
3. Polarization of ATM and the link to IR
Macrophages are extremely heterogenic in function and phenotype, and have his-
torically been characterized into two phenotypes; M1 and M2. M1 macrophages are 
often defined as ‘classically activated’ and are generally pro-inflammatory in func-
tion, with a vital role in eliminating pathogens and virus-infected cells. Whereas, M2 
macrophages and termed ‘alternatively activated’ are anti-inflammatory in function 
and promote tissue repair and wound healing. This is very simplified and dated 
model however, evidence now suggests that ATMs include highly plastic cell popu-
lations, with their phenotype largely dependent on the microenvironment of the 
AT. Whilst the exact number and function of ATM in the AT is evolving, it is clear 
there are distinct populations in the lean and obese AT, with unique tissue distribu-
tion, marker expression, transcriptional profiles and functions. Indeed, obese ATM 
display markers that are largely induced by their metabolic state rather than cytokine 
stimuli that classically polarise M1 and M2 cells [32].
3.1 M1 and M2 macrophage phenotypes
M1 macrophages are activated by signals associated with infection such as 
IFN-ɣ as well as bacterial-derived products such lipopolysaccharide (LPS) and free 
fatty acids (FFA). M1 macrophages are loosely identified by surface expression 
of F4/80+CD11C+ with high levels of MHC-II, CD68, CD80 and CD86 costimula-
tory molecules in addition to release of TNF-α and inducible nitric oxide synthase 
(iNOS) [36]. M2 macrophages are activated via Th2 cytokines, IL-4 and IL-13 as 
well as by parasitic products. M2 macrophages are loosely identified as F4/80+CD2
06+CD301+CD11C− and express genes encoding anti-inflammatory proteins such as 
Chil3, Arg1 and Il10 in mice [34]. A crucial transcription factor in M2 macrophage 
polarisation is peroxisome proliferator-activated receptor (PPAR-γ/δ), which can be 
driven by adipocyte derived IL-4 and IL-13 [37–39] (Figure 2). Some markers vary 
between mice and human macrophages. For example, there are no human homo-
logues of the M2-associated genes Chil3, Arg1 and Fizz1, with human M2 identified 
based on expression of tranglutaminase-2 (TGM2) and CD68 [40].
3.2 MMe and Mox macrophage phenotypes
Macrophages with a phenotype associated with obesity are induced by several 
metabolic stimuli such as FFA, high insulin and glucose, oxidised phospholipids and 
low-density lipoproteins. These macrophages display surface markers that are neither 
representative of typical M1 or M2 macrophages and give rise to a population of meta-
bolic activated (MMe) and oxidised (Mox) macrophages [41, 42] (Figure 2). Both 
these macrophage phenotypes are associated with a state of IR. MMe macrophages cell-
surface markers express ABCA1, CD36 and PLIN2 and are involved in the clearance of 
dead adipocytes through lysosomal exocytosis as well as potentiating inflammation. 
NADPH-oxidase-2 (NOX2) has been identified as a key driver of the functions of MMe 
macrophages, with Nox2-deficient mice displaying attenuated ATM inflammation 
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and improved glucose sensitivity in a model of diet-induced obesity, when compared 
to WT animals [41]. Mox macrophages are driven by oxidised phospholipids derived 
from oxidised low density lipoproteins (LDL) [43] and express surface markers Srnx-1 
and Txnrd-1 [42]. Mox macrophages have been studied primarily in the context of 
atherosclerosis, where the oxidation of accumulated LDL leads to enrichment of 
the tissue with oxidised lipids, causing the polarisation of macrophages towards a 
phenotype dependent on the transcription factor Nrf2 [43]. However, a recent paper 
identified that ATM with a Mox phenotype (CX3CR1negF4/80lowTxnrd1+HO1+) are the 
predominant phenotype present the AT of lean mice, driven by individual oxidised 
phospholipids in the AT [44]. It will be an interesting further area study to appraise the 
role of these novel macrophage phenotypes within the context of obesity and IR.
3.3 Regulators of macrophage polarization
Macrophage polarization has been well studied over the past decade leading to 
the discovery of several key regulators which orchestrate macrophage polarization, 
such as the Signal Transducer and Activator of Transcription (STAT) family, inter-
ferons, regulators of lipid metabolism, transcription factor families, microRNAs 
(miRNAs) and long non-coding RNAs [45] (Figure 3).
3.3.1 STAT family members
The Janus Kinase (JAK)/STAT signalling pathway transmits signals from extra-
cellular cytokines into the nucleus. Indeed, JAK/STATs are arguably the most widely 
studied pathway within the context of macrophage polarisation, with IFNɣ binding 
Figure 2. 
Adipose tissue macrophage (ATM) polarisation in lean and obese state. ATM originate from polarisation of 
‘M0’ macrophages. Depending on the stimuli and local environment facilitates the macrophage polarisation. 
Th1 cytokines, LPS, IFN-ɣ, TNF-α and IL-1β promote a M1 macrophage that is characterised by 
F4/80+CD11c+. In contrast, Th2 cytokines, IL-4 and IL-13 promote an M2 macrophage that is characterised 
by F4/80+CD206+CD301+CD11c−. Interestingly, in an obese state, the hypoxic environment and metabolic 
cues such as excess free fatty acids, high insulin and glucose, oxidised phospholipids and low-density 
lipoprotein, which promotes a metabolic activated (MME) or oxidised (MOX) macrophage. In the obese state, 
macrophages promote inflammation, IR and tissue damage. In contrast, in the lean state, macrophages promote 
ant inflammation, insulin sensitivity and tissue repair.
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to its receptor triggering activation of JAK1/2-mediated tyrosine phosphorylation 
and subsequent dimerization of STAT1 one of the first pathways to M1 polarisa-
tion identified [46]. In addition, LPS binding to TLR4 induces autocrine produc-
tion of IFN-ß that activates the type 1 IFN receptor triggering STAT1 and STAT2 
phosphorylation and heterodimerisation [47]. STAT3 has a dichotomous role in 
macrophage polarisation, it is the key transcriptional regulator in the production 
of the anti-inflammatory cytokine IL-10, which can drive an anti-inflammatory 
macrophage phenotype, however, STAT3 can also be activated by IL-6 and IFN-ß, 
inducing a pro-inflammatory phenotype [48]. Conversely, IL-4 and IL-13 induces 
M2 macrophage polarisation largely through induction of STAT6 and KLF4 via the 
dual catalytic activities of MCP-1-induced protein and inducing PPAR-ɣ [49–51].
3.3.2 Interferon regulatory factors
Interferon regulatory factors (IRFs) are intracellular proteins that regulate 
immune cell maturation and play a pivotal role in macrophage polarization. Two 
key and opposing IRFs in macrophage polarisation are IRF4 and IRF5, which 
directly compete for binding to MyD88 and subsequent transcription factors such 
as NFκB. Interestingly, IRF5 was shown to promote M1 macrophages, while IRF5 
expression was upregulated in obese individuals compared to lean individuals at 
both the mRNA and protein levels and is negatively associated with insulin sen-
sitivity [52–54]. It was also shown that IRF5 promotes inflammatory macrophage 
polarization by activating the transcription of IL-12 and repressing IL-10 [55]. 
Conversely, IRF4 acts as an antagonist of M1 macrophage polarisation, promot-
ing M2 macrophages [53, 54, 56]. In the context of obesity, macrophage-specific 
knockout of IRF4 resulted in significant IR and an increase in expression of 
pro-inflammatory genes [57]. Furthermore, IRF6 has also been implicated in 
Figure 3. 
Intracellular signalling of M1 and M2 macrophage polarisation. Respective intracellular key regulators of M1 
and M2 macrophage polarisation. Signal transducer and activator of transcription (STAT) family, interferons 
(IRFs) and microRNA (miRNAs).
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macrophage polarisation, promoting M1 macrophages due to suppression of PPARɣ 
expression, a critical regulator of M2 macrophages. Overexpression of IRF6 reduced 
M2 activation, whilst IRF6 knockdown enhanced M2 macrophage activation [58]. 
The impact of IRFs on macrophage polarisation and plasticity is clearly quite com-
plex and further studies will hopefully provide information on how IRFs function 
in different microenvironments, for example, in lean versus obese AT.
3.3.3 MicroRNAs
miRNA are short inhibitory non-coding RNAs (~22 nucleotides) that degrade 
specific mRNA targets or block RNA translation, and have also been implicated in 
driving macrophage polarisation. Indeed, miR-125b expression was shown to be 
upregulated in murine macrophages following IFN-ɣ stimulation and was identi-
fied to promote M1 macrophage polarisation, while suppressing IRF4, an important 
M2 transcription factor [59]. Additionally, miR-155 was also shown to promote M1 
polarisation with expression in murine macrophages increased upon TLR activation 
or stimulation with pro-inflammatory cytokines (TNF-α, IFN-β or IFN-ɣ) [45]. 
Whilst in human macrophages, miR-155 was shown to target IL-13Rα1 and inhibit 
STAT6 activation, thus inhibiting M2 macrophage polarisation [60]. Additionally, 
miR-9 enhances M1 macrophage polarisation by suppressing PPARδ [61]. Whilst 
miR-127 suppresses B-Cell lymphoma protein (Bc6), which promotes M1 polarisa-
tion [62]. Conversely, miR-124 promotes M2 polarisation via LPS-induced cytokine 
production by targeting STAT3 to decrease IL-6 production and reduce TNF-α [63]. 
Furthermore, miR-132, miR-146a and miR-223 induce M2 macrophages by inhibiting 
NF-κB [64–66].
3.4 Hypoxia and macrophage polarisation
Of interest in the context of obesity is the potential for hypoxia to influence 
macrophage polarisation of macrophages (Figure 2). Indeed, hypoxic areas in adi-
pose tissue occur in obese individuals when rapid tissue expansion occurs without 
sufficient accompanying blood flow to these areas. M1 macrophages display high 
expression levels of Hypoxia-related genes including Hif1α, which has been shown 
to induce a pro-inflammatory phenotype in macrophages via TLR4 activation, 
involving the PI3K/Akt signalling pathway [67, 68]. TLR4 expression in macro-
phages was shown to increase in a hypoxic environment [69]. Hif1α enhances the 
transcriptional activity of NF-κB, driving production of pro-inflammatory cyto-
kines and decreasing the induction of immune regulatory mediators [70]. In con-
trast, M2-like macrophages in obese individuals express Hif2α [71]. Indeed, HIF-2α 
is also upregulated under low oxygen levels [5]. It was shown that HIF-2α over-
expressing macrophages suppressed pro-inflammatory responses and improved 
IR. Whilst knockdown of HIF-2α in macrophages induced pro-inflammatory gene 
expression in adipocytes [71]. Thus, it was suggested that HIF-2α counteracts the 
pro-inflammatory responses to relieve obesity induced IR in AT [71].
3.5 IR and macrophage polarisation
Insulin acts in the adipose tissue to promote uptake and storage of fatty acids, 
stored as triglycerides, and inhibits the lipolysis of stored triglycerides. IR is a 
reduced response to insulin in the liver, muscle and AT, due to an impairment in the 
insulin-signalling pathway, leading to hyperglycaemia [72]. In obesity, the increased 
recruitment of macrophages to AT positively correlates with IR [4]. Indeed, 
obese mice show increased macrophage-mediated inflammation that resulted in 
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long-term IR [73], with elevated levels of FFA which activated CD36 expressing 
macrophages and adipocytes, inducing inflammation and impairing insulin signal-
ling [74]. In AT from lean states, the presence of M2 macrophages maintains insulin 
sensitivity via anti-inflammatory actions of IL-10 and STAT3 [25]. In obese individ-
uals, there is a change in adipocyte metabolism and gene expression. Consequently, 
there is increased lipolysis and release of FFA which can lead to TLR4 activation 
of M1 macrophages [75]. Indeed, TLR4 expression is increased on macrophages 
in obese individuals. In co-culture studies, it was shown that macrophage activa-
tion through TLR4 signalling increased secretion of pro-inflammatory cytokines, 
blocking the insulin signalling cascade [76, 77]. In obese individuals, the IκB kinase 
(IKK) complex is activated in macrophages resulting in phosphorylation of IκBα 
on Ser32 and 36, degrading IκBα and allowing NF-κB to translocate to the nucleus 
and upregulated target genes such as pro-inflammatory cytokines including TNF-α, 
IL-1β and IL-6 [78].
Increased expression of pro-inflammatory cytokines negatively affects insulin 
signalling pathways [79]. The effect of these cytokines on IR are seen locally in 
AT, but also systemically as they are released into circulation [76]. TNF-α phos-
phorylates insulin receptor substrates (IRS), consequently preventing downstream 
signalling via inhibiting IKK, c-Jun n-terminal kinase (JNK) and atypical protein 
kinase C (aPKC) [80]. Interestingly, males have been shown to have increased 
TNF-α plasma concentration compared to females, leading to the suggestion that 
obese males are more susceptible to develop IR [81]. IL-6 is increased in the serum 
of obese individuals and mice, with weight loss reducing circulating IL-6, which 
improves insulin sensitivity [82]. Systemic IR has also observed during pregnancy, 
puberty and during infection such as sepsis driven by TNF-α and IL-6 [83]. It is 
clear from such studies that the presence of pro-inflammatory cells and the release 
of pro-inflammatory cytokines lead to a loss of sensitivity to insulin and a state of 
IR. This is possibly the biggest incentive to therapeutically target the macrophages 
in cases of metabolic disease.
4. The metabolic signature of macrophages
Metabolism is a series of highly interconnected pathways that generate 
metabolic products such as energy and macromolecules from nutrients in the 
microenvironment. Whilst the metabolic pathways are plastic, cells, in particu-
lar macrophages, tend to utilise a pathway that suits their immediate energy 
requirements. M1 macrophages have huge metabolic demands, and rely largely 
on glycolysis, conversely, M2 macrophages meet their energy requirements using 
oxidative phosphorylation (OXPHOS) pathways. During glycolysis, extracellular 
glucose is taken up by the cell and converted to two molecules of pyruvate and ATP; 
NAD+ is converted to NADH+H+ regenerated through the breakdown of pyruvate 
to lactate. Glycolysis also provides the first molecule in the pentose-phosphate 
pathway, glucose-6-phosphate, which provides NADPH to maintain the cellular 
redox balance and the production of fatty acids. In M1 macrophages, the increased 
glucose consumption is associated with the capacity for rapid cytokine production 
and antimicrobial activity through ROS generation [84, 85]. Conversely, in the 
presence of oxygen cells produce ATP via the electron transport chain (ETC), which 
is linked to the tricarboxylic acid (TCA) cycle. The TCA cycle uses carbon sources, 
such as Acetyl CoA, glutamine or fatty acids to fuel a cycle which generates the 
reducing agents NADH and FADH2 that serve as electron carriers for the ETC for 
OXPHOS. Glycolysis is a poor producer of energy, with only two molecules of ATP 
per glucose molecule, compared to 36 molecules produced by OXPHOS. However, 
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the use of each pathway will depend on the environment and functional require-
ments of the cells, as glycolysis provides energy rapidly.
The TCA cycle is truncated in M1 macrophages, resulting in a reduced production 
of alpha-ketoglutarate (α-KG) and accumulation of citrate and succinate metabolites 
[86]. The accumulation of citrate leads to the production of the macrophage specific 
metabolite itaconic acid, which is a major feature of LPS stimulated macrophages 
[86]. The build-up of itaconic acid has been identified as a driver for succinate 
accumulation, through its ability to inhibit succinate dehydrogenase [87, 88]. The 
excess succinate leads to the induction of IL-1β through the stabilization of HIF-1a 
further enhancing inflammation in the macrophages [89]. Indeed, blocking glycoly-
sis reduces release of CCL2 from TNF-a or LPS stimulated adipocytes, providing 
further evidence for a link between metabolism and inflammation [90] (Figure 4).
Macrophage polarization is also influenced by the metabolism of arginine. 
M1 macrophages upregulated nitric oxide synthase (iNOS), which catabolize 
arginine to citrulline and nitric oxide (NO). This NO is important for intracellular 
killing of pathogens. In addition, M1 macrophages use the pentose phosphate 
pathway, which generates NADPH for the NADPH oxidase, which produces ROS 
and NO. Consequently, these metabolic pathways provide M1 macrophages with 
rapid energy. Conversely, in M2 macrophages, arginase-1 (Arg1) is induced which 
produces urea, ornithine and polyamines which are key in tissue repair [36, 91].
The metabolic profile of ATM alters dependent on the microenvironment of the 
AT. In mice, transcriptome and extracellular flux analysis have shown that in lean AT 
fatty acid oxidation, glycolysis and glutaminolysis all participate in cytokine release 
by ATM [92]. In obese AT, both glycolysis and OXPHOS are utilised, however gly-
colysis takes precedence, potentially due to the hypoxic environment in the AT [92].
Figure 4. 
Immunometabolic differences in M1 and M2 macrophages. M2 macrophages use OXPHOS and the TCA 
cycle to produce energy. They have increased ability to uptake free fatty acid (FFA) and fatty acid oxidation 
(FAO) to facilitate the TCA cycle. In contrast, M1 macrophages increase energy production oxidative glycolysis. 
M1 macrophages also have a ‘broken’ TCA cycle, resulting in accumulate of citrate and succinate. Increased 
succinate results in secretion of pro-inflammatory cytokine IL-1β via HIF-1α. TCA, tricarboxylic acid; 
HIF-1a, hypoxia-inducible factor-1a; a-KG, alpha-ketoglutarate.
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5.  Could targeting macrophages provide a therapeutic strategy in 
metabolic disorders?
As described above, as macrophages play a significant role in obesity and other 
metabolic disorders they are an attractive therapeutic target. The therapeutic strate-
gies that target macrophages look to re-educate polarized macrophages, depletion 
of polarized macrophages or silencing macrophages. Additionally, the link between 
macrophage polarization and cellular metabolism suggests a potential therapeutic 
strategy by modulating the macrophage metabolic state. There are several therapeu-
tic strategies commonly used to target macrophages such as depletion, proliferation, 
inflammation and gene silencing.
5.1 Macrophage depletion
It was shown that macrophages could be depleted in vivo by inducing apoptosis 
following accumulation of toxic particles [93]. Interesting, it was shown that by 
depletion of pro-inflammatory macrophages resulted in normalizing insulin sensi-
tivity in IR obese mice [94]. Furthermore, in obese mice, the depletion of visceral 
adipose tissue macrophages (VATMs) by Intraperitoneal injection of clodronate 
liposomes, results in improved systemic insulin sensitivity, glucose homeostasis 
and further blocked high-fat diet-induced weight gain [95, 96]. Consequently, 
depletion of VATMs also resulted in prevention of CLS in WAT and a low level of 
blood TNF-α [96]. However, liposomes treatment as a therapy is prone to degrada-
tion and significant risks of potential off-target effects. An alternative approach 
is altering macrophage proliferation, such as using a nanoparticle-based delivery 
of simvastatin, which may provide therapeutic benefit for atherosclerosis [97]. 
However, as previously mentioned, in obesity, macrophages are recruited from 
circulating monocytes, so reducing proliferation may not provide therapeutic 
benefit for IR [98].
5.2 Biological therapeutics
There are several orally active synthetic ligands for PPARɣ which are used to 
treat IR in patients with T2D. It has been shown in vivo that pioglitazone, belong-
ing to the chemical class thiazolidinediones, reduces LPS induced TLR2 and TLR4 
expression on peritoneal macrophages. Whilst in vitro, pioglitazone reduces the 
synthesis and gene expression of TLR2, TLR4, IL-1β, TNF-α, IL-6 and MCP-1 in 
human blood monocytes [99]. However, the use of thiazolidinediones like pio-
glitazone in clinical studies to treat T2D has resulted in increased cardiovascular 
events and death [100].
Clinical studies have shown that anti-inflammatories are efficacious in patients 
with systemic IR. Members of the interferon family have been used to suppress the 
release of pro-inflammatory cytokines, however, the use of type 1 interferons, as 
well as other anti-inflammatory strategies, is associated with cell toxicity in long-
term use. Recently studies using interferon tau (IFNT), an alternative member 
of the type 1 interferon family, in mice with diet-induced obesity show enhanced 
insulin sensitivity when compared to untreated mice. There was also a significant 
decrease in secretion of pro-inflammatory cytokines and increased M2 macro-
phages in AT, suggesting IFNT as a novel bio-therapeutic agent for treating obesity-
associated disorders [101].
Interestingly, yeast-derived β-glucans (Y-BGs) have been shown to be beneficial 
in models for obesity. In obese humans, Y-GBs administered orally increased AT 
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expression of anti-inflammatory cytokine IL-10 and serum IL-10 [102]. In addition, 
macrophages uptake of Y-GBs increased reactive oxygen species (ROS) formation, 
phagosomal maturation and induction of autophagy [103].
5.3 RNA interference
Another attractive therapeutic approach in targeting macrophage polarisation 
would be to use RNA interference (RNAi), which reduces gene expression. This 
approach could target the inflammatory mediators such as TNF-α, IL-6 and IL-1β 
[98]. Indeed, it was shown that intraperitoneal (i.p.) administration of small inter-
fering RNA (siRNA) selectively silenced genes such as TNF-α in epididymal ATM 
of obese mice and improved glucose tolerance [7]. Additionally, it was shown that 
i.p. administration of a rabies virus glycoprotein-derived acetylcholine receptor-
binding peptide delivers siRNA into ATM and peritoneal macrophages in HFD 
mice. This resulted in inhibition of ATM infiltration and reduced pro-inflammatory 
cytokines, thus improving glucose tolerance and insulin sensitivity [104].
5.4 Metabolic reprogramming
As stated previously, macrophage phenotypes have distinct metabolism path-
ways. Therefore, altering the metabolic state of macrophages provides a potential 
therapeutic approach to metabolic disorders. Indeed, the strong link between 
macrophage polarization and cellular metabolism makes altering the metabolic 
state of the cells an attractive therapeutic prospect. To prove this principle, inducing 
oxidative metabolism in M1 macrophages has been shown to shift the phenotype to 
an M2 profile [105], while blocking oxidative metabolism in macrophages inhibits 
the M2 phenotype and drives the M1 macrophage phenotype. Furthermore, it was 
shown that by driving macrophage metabolism with glucose, insulin and fatty acids 
resulted in an increased pro-inflammatory ATM phenotype in obese mice [32].
Modulation of the metabolic pathways in macrophages has been studied 
extensively in recent years to assess the extent to which inflammatory status can 
be influenced by the metabolic profile of the cells. Glucose transporter (GLUT)-1 
is upregulated in macrophages localised to the CLS in inflamed obese AT. In vitro 
studies show that overexpression of GLUT1 increases glucose uptake in the cells and 
induces release of pro-inflammatory cytokines, linking the metabolic phenotype 
with the inflammatory function of the cells [106]. Furthermore, knockout of fatty 
acid transporter protein (FATP)-1 expression, which is elevated in M2 macrophages, 
is associated with priming of macrophages towards an M1 phenotype, upregulating 
expression of NOS1 [107]. Further pathways of current interest to therapeutically 
target include Notch, carbohydrate kinase-like protein (CARKL), mammalian target 
of rapamycin (mTOR), IL-4 and IL-10, all of which show intricate links between the 
metabolic and inflammatory pathways in macrophages [108–112].
6. Conclusions
Obesity has long been considered a low-grade systemic inflammatory condi-
tion, which appears to be mediated largely through the prominent populations of 
ATM. Alterations in environmental cues, including changes in metabolites, the 
microbiota and inflammatory stimuli act to influence the ATM, coordinating the 
recruitment of pro-inflammatory monocytes and altering the metabolic state of 
ATM. While in lean individuals the resident ATM function to clear dead adipocytes 
and sequester excess lipids from the AT to maintain homeostasis within the AT, 
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the recruited inflammatory ATM release pro-inflammatory cytokines to induce 
inflammation within the AT and are involved in the pathogenic remodelling of 
the AT. This state of inflammation within the ATM is largely associated with IR 
and metabolic dysfunction through interference with insulin signalling pathways. 
Macrophages are heterogenous and extremely plastic and as such it has historically 
been difficult to define subsets. With the use of transcriptional and metabolic 
profiling it is now becoming possible to appraise the full role of ATM in obesity. 
This knowledge will aid the search for novel therapeutics targeting the metabolic 
capacity and inflammatory potential of ATM, restoring the homeostatic functions 
of resident lean ATM, to modulate obesity.
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